A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
RIO is a placebo-controlled double-blinded two arm prospective phase II randomised controlled
trial . This study will test the use of broadly neutralising antibodies (bNAbs) in
participants with treated primary HIV infection (PHI).
Phase:
Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborators:
Bill and Melinda Gates Foundation Rockefeller University University of Oxford